Background: Primary SS (pSS) is the second most common systemic autoimmune disease after RA. However, the mechanisms of pSS pathogenesis remain poorly understood. The United Kingdom Primary Sjö gren's Syndrome Registry (UKPSSR) aims to facilitate research and improve our understanding of pSS by providing a large cohort of clinically well-characterized pSS patients and matched healthy controls. The project is an initiative of the United Kingdom Sjö gren's Interest Group (UKSIG) and is funded by the Medical Research Council. Methods: PSS patients were recruited from 30 centres across the UK, the majority of whom fulfilled the AECG criteria (Table 1) . Extensive subjective and objective clinical data were collected for all patients including demographics, co-morbidity, biopsy status, Schirmer's test value and treatment history. Disease activity (ESSDAI, SCAI, SSDAI) and disease damage (SDI, SSDDI) scores were calculated for all patients in the cohort. In addition, patient-reported outcomes were calculated for symptom assessment (PROFAD-SSI, ESSPRI, Epworth sleepiness scale, OGS), quality of life (EQ-5D, SF-36), and, anxiety and depression (HADS). An optional cardiovascular risk assessment was carried out on a subset of the patients. Age-, sex-and ethnicitymatched healthy controls were also recruited. Finally, blood samples, comprising peripheral blood mononuclear cells, whole blood DNA, whole RNA and serum were bio-banked for all of the patients and controls of the cohort. Results: The UKPSSR is a national cohort and research biobank of approximately 700 clinically well-characterized pSS patients and around 350 matched healthy controls (http://www.sjogrensregistry.org/index.php). To date the cohort has been used to study several aspects of pSS pathogenesis and its clinical features, including healthrelated utility values, autonomic symptom burden and genetic variation in pSS.
Conclusion:
The UKPSSR cohort provides a resource to enhance our understanding of pSS through facilitating high-quality clinical and academic research. It is hoped that the UKPSSR will serve as a foundation for the formation of a more extensive collaborative research network for pSS. Background: The availability of whole genome sequences has spurred a revolution in biological analyses facilitating the development of technologies for the study of genes and proteins on a cell-wide basis. Consequently, a range of biological data, including metabolic and signalling pathways, experimental interaction data, and protein annotations, is available. There is considerable discordance in data from largescale gene expression studies of primary SS (pSS). Combining these data with other types of genome-wide information can provide a more complete view of the cell in order to identify the key genes and biological processes that are involved in the pathogenesis of pSS. Methods: In this study, a list of genes, found to be differentially expressed between pSS patients and healthy controls in four largescale microarray studies, was derived from the literature. KEGG metabolic pathway and GO biological process enrichment analyses were then performed for the individual datasets and the combined pSS-associated gene list. Using all the available human interaction data from the BioGRID database, a functional interaction network was produced in which nodes represented genes or gene products, and edges represented any type of interaction between the nodes. The network was then annotated based on the pathway and process enrichment results. Finally, the network was filtered to identify patterns of connectivity between pSS-associated genes and the enriched cellular processes. Results: Despite the overlap of differentially expressed genes in the four datasets being relatively low, there is significant overlap between the GO biological process enrichments of these genes, with the majority being related to immune processes. Significant enrichment of immune-related KEGG pathways was also observed for the pSSassociated gene list. Following network filtering, a cluster of the pSSassociated genes was identified. All four gene expression datasets were represented within this connected component. Several clusters of genes annotated to the processes innate immune response, multiorganism process, response to virus and response to stress were observed in the integrated network, and network filtering revealed patterns of interaction between these clusters and the pSS-associated genes. In particular, several pSS-associated genes were found to lie between clusters of genes annotated to the immune/stress responses and clusters involved in multi-organism processes. Conclusion: Gene enrichment and network analyses of the pSSassociated genes suggest that the innate immune responses, multiorganism processes, and the responses to virus and to stress are likely to be involved in pSS pathogenesis. Integration of multiple types of data in this manner can aid in the interpretation of results since combining diverse data sources reveals global properties not evident from a single data source. Future studies may benefit from incorporating additional detailed clinical data during the analysis of expression data in order to elucidate the relationship between gene expression and clinical phenotype. Background: AS is a chronic inflammatory condition associated with trabecular bone loss, osteoporosis and a high risk of fracture. However, assessment of vertebral bone mineral density using standard anterior-posterior (AP) dual energy X-ray absorptiometry (DEXA) may be of limited use in those with vertebral syndesmophytes. These may lead to increased X-ray absorption and overestimation of vertebral bone density. The aim of this study was to explore relationship between symptom duration and bone mineral density (BMD) at the hip and spine in a cross-sectional cohort of patients with AS. Methods: Patients attending AS clinics who had undergone DEXA assessment of bone mineral density were identified and symptom duration at time of DEXA recorded. Prevalence of low BMD (defined as t-score -1) and osteoporosis (defined as t-score -2.5) was identified.
The relationship between site of lowest BMD and symptom duration was explored. Logistic regression was used to explore associations between Low BMD at: (i) hip, and (ii) spine, and increasing symptom duration in 10 year categories, adjusting for age at time of scan.
Results: 111 patients with AS, mean age 50.3 (S.D. 12.9), and 76.6% male were identified. The mean symptom duration at DEXA was 21.6 years (S.D. 11.8) which was similar for both males and females. The spine was the site of lowest BMD for 32 (62.8%) with symptom duration <20 years (n ¼ 51), and 17 (28.3%) with symptom duration ! 20 years (n ¼ 60) (chi2 ¼ 13.24, P < 0.005). Low BMD at the hip was observed in 55 (49.6%) of the cohort with 13 (11.7%) having BMD -2.5. Low BMD at the spine was seen in 49 (44.1%) with 12 (10.8%) in osteoporotic range. Increasing disease duration was not significantly associated with low BMD at the hip and spine in the whole cohort. However, during the first 20 years of symptoms with AS, each additional 10 years of symptom duration was associated with osteopenia in the vertebra. This association remained after adjusting for age [OR adj 3. 
PLASMA MICROPARTICLE LEVELS ARE NOT RAISED IN PATIENTS WITH ANKYLOSING SPONDYLITIS
Nicholas A. Bradley Intravesicular contents such as microRNA and prothrombotic factors are implicated in the development of cardiovascular disease, and patients with inflammatory arthropathies have increased risk of adverse cardiovascular event, a proportion of which remains when traditionally described risk factors are discounted. Whilst inflammatory conditions such as RA have had extensive microparticle investigation, to date only one study describes levels of microparticles in AS, showing no significant difference in counts between cases and controls. This study aims to further characterize levels of microparticles in AS patients, and add novel data describing their cellular origin and contents (including microRNA analysis). Methods: 11 patients diagnosed with AS under the care of University Hospital Aintree (UHA) rheumatology department were recruited in the outpatient setting, and matched for age and gender with 10 controls recruited from staff at UHA Clinical Sciences department. Mean ages were 46.5 and 41.4 in cases and controls respectively. Baseline data on disease activity cardiovascular risk factors and demographic characteristics were obtained from case notes at recruitment. Mean disease activity at recruitment (BASDAI) was 4.3. 6 patients were receiving anti-TNF therapy. Microparticles were isolated from venous blood by serial centrifugation. These were resuspended in HBSS and analysed for count, CD surface markers and annexin-V (AV) fluorescence using flow cytometry.
Results: The data generated were not normally distributed thus figures quoted are median (IQR), and the Mann-Whitney U test used to assess statistical significance. Microparticle counts per ml of blood were 2.29 Â 10 6 (4.16 Â 10 5 ) and 2.95 x10 6 (1.88 Â 10 5 ) in cases and controls respectively (P ¼ 0.0843). CD proteins CD4, CD62, CD14 and VCam1 showed increased expression in patients' microparticles compared with controls (P < 0.05), whilst CD41 and CD54 showed decreased expression in patients (P < 0.05). AV fluorescence (given as % positive expression) was 67.58% (33.42%) vs 98.27% (4.37%) in cases and controls (P ¼ 0.0014). No significant differences between high and low disease activity cohorts or between patients receiving biologic vs nonbiologic therapies were observed. Conclusion: These data show that whilst there is no significant difference in number of microparticles in AS patients compared with controls, their origin is different both in terms of the cellular source and the mechanism behind their formation; increased AV fluorescence suggests increased proportions of microparticles formed under apoptotic stimulus in cases compared with controls. Our intended recruitment of more patients to increase sample size may reveal significant results not yet described. 
